European Companies Search Engine

EU funding (€12M): EU Patient- cEntric clinicAl tRial pLatform Hor1 Nov 2019 EU Research and Innovation programme "Horizon"

Overview

Text

EU Patient- cEntric clinicAl tRial pLatform

EU-PEARL has the ambition of transforming the current approach of conducting single-compound clinical trials into the use of cross-company Integrated Research Platforms (IRPs), taking into consideration both patients’ interests and the opportunities from novel molecules for addressing medical needs. Patient-centric data and knowledge sharing have the potential to accelerate the development of new treatments and reduce the operational costs of clinical trials. EU-PEARL will improve clinical effectiveness, patients’ satisfaction and societal access to timely and affordable medicines and it will shape the clinical trials of the future. This will change the industry paradigm from competition to cooperation in four disease areas and provide the framework for designing IRPs in other disease areas. The main objectives of EU-PEARL are: (1) To create a reusable, accessible and sustainable modular IRP for the design and execution of patient-centric, cross- company IRP in any disease area with unmet needs; (2) To set up the open, dynamic, patient inclusive IRP governance structure that will manage the appropriate regulatory, ethical, legal, statistical and data utilisation requirements of the IRP; (3) To disseminate and exploit the EU-PEARL paradigm through the provision of the necessary common tools, procedures, expertise and operational skills working to the highest scientific, regulatory and ethical standards and best practices, developed jointly by public and industry partners in a consensus-based approach; and (4) To create trial-ready IRP networks in the four disease areas of Major Depressive Disorder (MDD), Tuberculosis (TB), Non-Alcoholic Steatohepatitis (NASH) and Neurofibromatosis (NF).


Funded Companies:

Company name Funding amount
Abbvie Inc. €0.00
Allergan Ltd. €0.00
Assistance Publique Hopitaux de Paris €619,749
Astrazeneca AB €0.00
Berry Consultants LLP €196,250
Bundesinstitut FUR Impfstoffe UND Biomedizinische Arzneimittel €317,625
Charite - Universitaetsmedizin Berlin €539,000
Children'S Tumor Foundation €0.00
Custodix N.V. €106,248
Documental OÜ €129,158
Eatris Eric €775,625
Ecrin European Clinical Research Infrastructure Network €426,875
Erasmus Universitair Medisch Centrum Rotterdam €899,875
European Aids Treatment Group e. V. €0.00
Euroscan International Network e. V. €117,500
Fondation Cardiometabolisme Nutrition €0.00
Forum des Patients Europeens €459,250
Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca €2,182,245
Global Alliance FOR TB Drug Development NON Profit Organisation €0.00
Information Technology FOR Translational Medicine (Ittm) SA €184,970
Institut de Recherches Internationales Servier €0.00
Janssen Pharmaceutica N.V. €0.00
Katholieke Universiteit Leuven €186,375
King's College London €612,078
Ludwig-Maximilians-Universitaet Muenchen €274,750
Medizinische Universitaet Wien €831,375
Novartis Pharma AG €0.00
Novo Nordisk A/S €0.00
Otsuka Novel Products GmbH €0.00
Pfizer Ltd. €0.00
Sanofi-Aventis Recherche & Developpement €0.00
Springworks Therapeutics Inc. €0.00
Synapse Research Management Partners SL €97,700
Teamit Research SL €985,181
Teva Pharmaceutical Industries Ltd. €0.00
The Chancellor, Masters and Scholars of the University of Oxford €114,625
THE European Institute for Innovation Through Health Data €751,625
The University of Manchester €40,000
Universita Degli Studi Di Milano €145,250
Universita Vita-Salute SAN Raffaele €734,250
University of Newcastle Upon Tyne €277,375

Source: https://cordis.europa.eu/project/id/853966

The filing refers to a past date, and does not necessarily reflect the current state.